Technical Analysis for EPZM - Epizyme, Inc.
|Grade||Last Price||% Change||Price Change|
EPZM closed unchanged on Friday, January 18, 2019, on 65 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
|See historical EPZM trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 18||Wide Bands||Range Expansion||0.00%|
|Jan 18||Overbought Stochastic||Strength||0.00%|
|Jan 17||180 Bullish Setup||Bullish Swing Setup||0.00%|
|Jan 17||Narrow Range Bar||Range Contraction||0.00%|
|Jan 17||NR7||Range Contraction||0.00%|
|Jan 17||Wide Bands||Range Expansion||0.00%|
|Jan 17||Overbought Stochastic||Strength||0.00%|
|Jan 17||Down 3 Days in a Row||Weakness||0.00%|
|Jan 17||Down 4 Days in a Row||Weakness||0.00%|
|Jan 16||Multiple of Ten Bearish||Other||-0.83%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Epizyme, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, planning, and commercialization of various personalized therapeutics for the treatment of patients with genetically defined cancers. Its principal product candidates under development include EPZ-5676, an intravenously administered small molecule inhibitor of DOT1L that is in Phase I clinical trials for the treatment of mixed lineage rearranged leukemia (MLL-r); and EPZ-6438, an orally available small molecule inhibitor of EZH2 for the treatment of non-Hodgkin lymphoma patients caused by an oncogenic point mutation in EZH2. The company has strategic collaboration and license agreements with Celgene Corporation and Celgene International Sàrl, as well as Glaxo Group Limited to discover, develop, and commercialize small molecule HMT inhibitors; and Eisai Co., Ltd. (Eisai) to license its EZH2 program. It also has a companion diagnostic collaboration with Abbott Molecular Inc. for the development of a companion diagnostic to identify patients with the MLL-r genetic alteration targeted by EPZ-5676; and with Roche Molecular Systems, Inc., as well as with Eisai for the development and commercialization of a companion diagnostic for use with EPZ-6438 product candidate. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more EPZM news...
|52 Week High||21.4|
|52 Week Low||5.14|
|200-Day Moving Average||11.3109|
|50-Day Moving Average||7.3484|
|20-Day Moving Average||7.8095|
|10-Day Moving Average||9.608|
|Average True Range||0.6816|
|Chandelier Exit (Long, 3 ATRs )||8.4252|
|Chandelier Exit (Short, 3 ATRs )||7.1848|
|Upper Bollinger Band||11.6362|
|Lower Bollinger Band||3.9828|
|Percent B (%b)||0.73|
|MACD Signal Line||0.6447|
|Market Cap||558.94 Million|
|Num Shares||58.5 Million|
|Price-to-Earnings (P/E) Ratio||-4.62|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||10.18|
|Resistance 3 (R3)||10.18||9.98||10.07|
|Resistance 2 (R2)||9.98||9.82||9.98||10.04|
|Resistance 1 (R1)||9.77||9.73||9.67||9.77||10.00|
|Support 1 (S1)||9.36||9.41||9.26||9.36||9.12|
|Support 2 (S2)||9.16||9.32||9.16||9.08|
|Support 3 (S3)||8.95||9.16||9.05|
|Support 4 (S4)||8.95|